Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions
Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore
Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations
Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), at this time introduced they’ve signed a binding Letter of Intent for a strategic collaboration to carry GRAIL’s GalleriⓇ multi-cancer early detection (MCED) take a look at to key Asian markets. SCT and SEC have additionally agreed to take a position $110 million into GRAIL, a healthcare firm whose mission is to detect most cancers early when it may be cured, at a worth of $70.05 per share of widespread inventory.1
“Guided by its commitment to advancing next-generation bio-technologies and improving quality of life, Samsung C&T has continuously invested in innovative companies. The collaboration with GRAIL represents a significant new step—moving beyond investment to a strategic business partnership that provides Samsung with a strong foothold for expanding into the cancer screening field and delivering one of these promising technologies to customers in South Korea and across Asia.” stated Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T.
Subject to last execution of definitive agreements, GRAIL and SCT will work as unique companions to commercialize the Galleri take a look at in South Korea, with a doable extension into different Asian geographies, together with Japan and Singapore. SCT will undertake key actions to drive adoption of Galleri . Initially, exams can be carried out in GRAIL’s medical laboratory in Research Triangle Park, North Carolina.
“We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea,” stated Sir Harpal Kumar, President, International Business & Biopharma, at GRAIL. “Samsung’s significant equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets.”
In addition, SEC and GRAIL intend to discover potential strategic and operational collaborations resembling supporting longitudinal genomic-lifestyle medical analysis, and the mixing of SEC’s well being information platform with GRAIL’s applied sciences and information.
“Our investment in and strategic cooperation with GRAIL is part of our vision to improve the health of billions of people. A potential collaboration with GRAIL could allow for the integration of our AI, our digital care platform, and device ecosystem with GRAIL’s clinical genetic data and technology, which could allow us to provide a level of personalization for our users to help them better understand their health,” stated Hon Pak, Senior Vice President and Head of Digital Health Team, Mobile eXperience Business, at Samsung Electronics.
The phrases of the collaborations are set forth within the time period sheets between the events. Definitive agreements can be negotiated in good religion pursuant to the time period sheet and are meant to be entered into in early 2026. Commercial operations will start quickly after execution. Within South Korea, and doubtlessly Japan and Singapore, GRAIL will accomplice with SCT as its sole distributor, topic to sure necessities, and GRAIL’s Galleri take a look at would be the unique MCED take a look at distributed by SCT.
The funding is topic to execution of the definitive collaboration agreements between the events, in addition to customary closing circumstances and regulatory approvals. The funding is anticipated to shut in early 2026.
Latham & Watkins served as authorized advisor and Morgan Stanley & Co. LLC served as monetary advisor to GRAIL. Samsung was suggested by Covington & Burling, BKL, and E&Y Han Young (Korea).
1…
